Autonomic Nervous System Drugs Practice Questions

Q: An elderly male is diagnosed with benign prostatic hypertrophy. Which drug will provide the fastest and greatest symptomatic relief for this patient?

Terazosin. **Explanation:** **1. Why Terazosin is correct:** Benign Prostatic Hypertrophy (BPH) involves two components: a **static** component (enlarged prostate gland) and a **dynamic** component (increased smooth muscle tone in the bladder neck and prostatic urethra). **Terazosin** is a long-acting, selective **$\alpha_1$-adrenergic blocker**. By blocking $\alpha_1$ receptors, it causes rapid relaxation of the smooth muscles in the bladder neck and prostate. This reduces urethral resistance and provides **immediate symptomatic relief** (within days) of obstructive symptoms like hesitancy and weak stream. **2. Why the other options are incorrect:** * **Finasteride:** This is a **5-$\alpha$ reductase inhibitor** that prevents the conversion of testosterone to dihydrotestosterone (DHT). While it treats the "static" component by shrinking the prostate over time, it takes **6–12 months** to show clinical benefit. It is not used for fast relief. * **Desmopressin:** An ADH analogue used primarily for central diabetes insipidus or nocturnal enuresis in children. It does not address the underlying pathophysiology of BPH. * **Sildenafil:** A PDE-5 inhibitor used for erectile dysfunction. While Tadalafil (another PDE-5 inhibitor) is FDA-approved for BPH, Sildenafil is not the standard first-line choice for rapid symptomatic relief compared to alpha-blockers. **3. Clinical Pearls for NEET-PG:** * **First-Dose Phenomenon:** Alpha-blockers like Terazosin and Doxazosin can cause **orthostatic hypotension**. Patients should be advised to take the first dose at bedtime. * **Uro-selectivity:** **Tamsulosin** is a selective $\alpha_{1A}$ blocker. It is "uro-selective," meaning it has less effect on systemic blood pressure compared to Terazosin. * **Combination Therapy:** For patients with very large prostates, a combination of an $\alpha$-blocker (for fast relief) and a 5-$\alpha$ reductase inhibitor (for long-term size reduction) is often used.

Q: What is the rate-limiting step in the synthesis of norepinephrine?

Conversion of tyrosine to DOPA. ### Explanation The synthesis of norepinephrine (catecholamine synthesis) follows a specific enzymatic pathway. Understanding the regulatory steps is crucial for NEET-PG pharmacology. **Why Option B is Correct:** The conversion of **Tyrosine to DOPA** (Dihydroxyphenylalanine) is the **rate-limiting step**. This reaction is catalyzed by the enzyme **Tyrosine Hydroxylase**. It is considered the "bottleneck" of the pathway because it is the slowest step and is subject to feedback inhibition by the end-products (norepinephrine and dopamine). In clinical practice, the drug **Metyrosine** inhibits this enzyme and is used in the management of pheochromocytoma. **Analysis of Incorrect Options:** * **Option A:** Conversion of phenylalanine to tyrosine occurs primarily in the liver via *phenylalanine hydroxylase*. While it provides the precursor, it is not the regulatory step for catecholamine synthesis in nerve terminals. * **Option C:** Conversion of DOPA to dopamine is catalyzed by *DOPA decarboxylase*. This step is very rapid and is the target of the drug **Carbidopa** (used in Parkinson’s disease to prevent peripheral conversion of Levodopa). * **Option D:** Conversion of dopamine to norepinephrine occurs inside the synaptic vesicles via *Dopamine β-hydroxylase*. While essential, it is not the primary rate-limiting point. **High-Yield Clinical Pearls for NEET-PG:** 1. **VMAT (Vesicular Monoamine Transporter):** Transports dopamine into vesicles; inhibited by **Reserpine**. 2. **Final Step:** In the adrenal medulla, norepinephrine is converted to epinephrine by **PNMT** (Phenylethanolamine N-methyltransferase), an enzyme induced by cortisol. 3. **Storage:** Norepinephrine is stored in vesicles complexed with **ATP and Chromogranin A** in a 4:1 ratio. 4. **Termination:** The primary mechanism for terminating norepinephrine action is **uptake-1 (reuptake)** into the presynaptic terminal, not enzymatic degradation.

Q: Which among the following is NOT a neuromuscular blocking agent?

Neostigmine. **Explanation:** The core of this question lies in distinguishing between drugs that **cause** neuromuscular blockade and those used to **reverse** it. **1. Why Neostigmine is the correct answer:** Neostigmine is an **Acetylcholinesterase (AChE) inhibitor**. It works by preventing the breakdown of acetylcholine (ACh) at the neuromuscular junction. This increases the concentration of ACh, which competes with non-depolarizing blockers to restore muscle function. Therefore, Neostigmine is a **reversal agent**, not a neuromuscular blocking agent (NMBA). **2. Analysis of incorrect options:** * **Pipecuronium:** A long-acting, non-depolarizing NMBA belonging to the aminosteroid group. It is chemically related to Pancuronium but lacks significant cardiovascular side effects. * **Gantacurium:** A newer, ultra-short-acting non-depolarizing NMBA (asymmetric α-chlorofumarate). It was developed to provide a rapid onset and short duration of action, similar to Succinylcholine but without the side effects of depolarization. * **d-TC (d-Tubocurarine):** The prototype non-depolarizing NMBA (isoquinoline derivative). It acts by competitively blocking nicotinic receptors ($N_m$) at the motor endplate. **3. NEET-PG High-Yield Pearls:** * **Classification:** NMBAs are divided into **Depolarizing** (Succinylcholine) and **Non-depolarizing** (Isoquinolines like d-TC, Atracurium; Aminosteroids like Vecuronium, Rocuronium). * **Reversal:** Neostigmine is always co-administered with an antimuscarinic (usually **Glycopyrrolate** or Atropine) to prevent bradycardia and excessive secretions caused by systemic ACh accumulation. * **Drug of Choice:** **Rocuronium** is often preferred for rapid sequence intubation when Succinylcholine is contraindicated. * **Sugammadex:** A novel reversal agent specifically for Rocuronium and Vecuronium; it works by chelation rather than AChE inhibition.

Q: Increasing the concentration of norepinephrine in adrenergic synapses leads to which of the following effects?

Activation of presynaptic Gi (C) coupled receptors. ### Explanation **Correct Option: D. Activation of presynaptic Gi (C) coupled receptors** The regulation of norepinephrine (NE) release is governed by a **negative feedback mechanism**. When NE concentrations increase in the synaptic cleft, the excess NE binds to **presynaptic Alpha-2 ($\alpha_2$) receptors**. These receptors are **Gi-protein coupled**. Activation of the Gi pathway inhibits the enzyme adenylyl cyclase, leading to decreased levels of cAMP and closure of calcium channels. This effectively inhibits further exocytosis of NE, acting as an "autoinhibitory" brake. **Analysis of Incorrect Options:** * **A & B (Activation of Tyrosine Hydroxylase/Dopa Decarboxylase):** Tyrosine hydroxylase is the rate-limiting enzyme in catecholamine synthesis. High levels of NE actually cause **feedback inhibition** of tyrosine hydroxylase (not activation) to prevent overproduction of the neurotransmitter. * **C (Increased release of NE):** Increasing the concentration of NE triggers the negative feedback loop mentioned above. Therefore, it leads to a **decrease** in further release, not an increase. **NEET-PG High-Yield Pearls:** * **Presynaptic Receptors:** While $\alpha_2$ is the primary inhibitory receptor (Gi), **Presynaptic Beta-2 ($\beta_2$) receptors** exist and actually *increase* NE release (Gs coupled). * **Mnemonic for G-Proteins:** **QISS** ($\alpha_1$=Gq, $\alpha_2$=Gi, $\beta_1$=Gs, $\beta_2$=Gs). * **Clinical Correlation:** Drugs like **Clonidine** and **Methyldopa** are $\alpha_2$ agonists; they mimic this high-NE state to decrease sympathetic outflow, making them useful in treating hypertension. * **Reserpine:** Inhibits VMAT (vesicular monoamine transporter), preventing NE storage and leading to depletion.

Q: All of the following drugs cause mydriasis except?

Pilocarpine. **Explanation:** To understand mydriasis (pupillary dilation), one must distinguish between the two muscles of the iris: the **Dilator Pupillae** (Sympathetic control via $\alpha_1$ receptors) and the **Sphincter Pupillae** (Parasympathetic control via $M_3$ receptors). **Why Pilocarpine is the correct answer:** Pilocarpine is a **direct-acting cholinergic agonist**. It stimulates the $M_3$ muscarinic receptors on the Sphincter Pupillae, causing it to contract. This results in **miosis** (pupillary constriction), not mydriasis. It also causes contraction of the ciliary muscle, leading to accommodation for near vision and decreased intraocular pressure, making it useful in glaucoma. **Analysis of incorrect options:** * **Phenylephrine:** A selective $\alpha_1$ agonist. It stimulates the Dilator Pupillae directly, causing **active mydriasis** without affecting accommodation (no cycloplegia). * **Epinephrine:** A non-selective adrenergic agonist. It acts on $\alpha_1$ receptors to cause mydriasis. It is often used in intraocular surgeries to maintain pupillary dilation. * **Atropine:** An anticholinergic (muscarinic antagonist). By blocking $M_3$ receptors on the Sphincter Pupillae, it allows the dilator muscle to dominate, resulting in **passive mydriasis**. It also causes **cycloplegia** (paralysis of accommodation). **High-Yield Clinical Pearls for NEET-PG:** 1. **Active vs. Passive Mydriasis:** Sympathomimetics (Phenylephrine) cause active mydriasis; Parasympatholytics (Atropine) cause passive mydriasis. 2. **Drug of choice for Fundus examination:** Tropicamide (fastest onset, shortest duration). 3. **Phenylephrine** is preferred when you want to dilate the pupil without blurring the patient's vision (as it spares the ciliary muscle). 4. **Miosis Mnemonic:** "Point" (Parasympathetic/Pilocarpine = Pinpoint/Miosis); "Dilation" (Sympathetic = Dilation).

Q: Which of the following is an example of antisialogogues used to control moisture during orthodontic bonding?

Banthine. **Explanation:** The correct answer is **Banthine (Methantheline bromide)**. **1. Why Banthine is correct:** Banthine is a synthetic **antimuscarinic (anticholinergic)** agent. In dentistry and orthodontics, it is used as an **antisialogogue**—a drug that reduces the flow of saliva. During orthodontic bonding, maintaining a dry field is critical for the bond strength of resins. Banthine works by competitively inhibiting M3 muscarinic receptors on salivary glands, thereby blocking parasympathetic stimulation and significantly decreasing salivary secretions. **2. Analysis of Incorrect Options:** * **A. Epinephrine:** A sympathomimetic (alpha and beta agonist). While it causes vasoconstriction (often used with local anesthetics to reduce bleeding), it does not effectively suppress salivary gland secretion for bonding procedures. * **B. Betamethasone dipropionate:** A potent topical corticosteroid used for inflammatory skin conditions or oral mucosal lesions (like lichen planus). It has no effect on salivary flow. * **C. Paracetamol:** A non-opioid analgesic and antipyretic. It inhibits prostaglandin synthesis in the CNS but lacks anticholinergic properties. **3. NEET-PG High-Yield Pearls:** * **Propantheline (Pro-Banthine)** is a related quaternary ammonium compound often used similarly to Methantheline. * **Contraindications:** Antisialogogues (anticholinergics) should be avoided in patients with **Glaucoma** (may increase intraocular pressure) and **Prostatic Hypertrophy** (may cause urinary retention). * **Other Antisialogogues:** Atropine and Glycopyrrolate are also used pre-operatively to reduce secretions, with Glycopyrrolate being preferred as it does not cross the blood-brain barrier (less CNS side effects).

Q: Which drug inhibits the release of acetylcholine at the neuromuscular junction?

Botulinum toxin. **Explanation:** The release of Acetylcholine (ACh) from the presynaptic nerve terminal involves a complex process of vesicle docking and fusion. **1. Why Botulinum Toxin is Correct:** Botulinum toxin (produced by *Clostridium botulinum*) acts by proteolytically cleaving **SNARE proteins** (specifically SNAP-25, synaptobrevin, and syntaxin). These proteins are essential for the fusion of ACh-containing vesicles with the presynaptic membrane. By preventing this fusion, the toxin effectively **inhibits the release of ACh** into the synaptic cleft, leading to flaccid paralysis. **2. Why the Other Options are Incorrect:** * **Hemicholinium (B):** Inhibits the **uptake of choline** into the nerve terminal. This is the rate-limiting step in ACh synthesis, but it does not directly block the release of pre-formed ACh. * **Atropine (C):** A competitive **muscarinic receptor antagonist**. It blocks the action of ACh at the post-junctional receptor site (primarily parasympathetic effector organs), not its release. It has no significant effect at the nicotinic receptors of the neuromuscular junction (NMJ). * **Vesamicol (D):** Inhibits the **storage of ACh** into vesicles by blocking the VAT (Vesicle Associated Transporter). **Clinical Pearls for NEET-PG:** * **Black Widow Spider Venom (α-latrotoxin):** Acts opposite to Botulinum; it causes **massive release** of ACh, leading to spastic paralysis. * **Lambert-Eaton Syndrome:** An autoimmune condition where antibodies attack P/Q-type voltage-gated calcium channels, also resulting in decreased ACh release. * **Therapeutic uses of Botulinum (Botox):** Used in focal dystonias, blepharospasm, achalasia cardia, spasticity, and cosmetic procedures.

Q: Which condition is treated with anticholinesterase drugs?

Alzheimer's disease. **Explanation:** **1. Why Alzheimer’s Disease is Correct:** Alzheimer’s disease is characterized by a deficiency of cholinergic transmission in the brain (specifically in the hippocampus and cortex). **Anticholinesterase drugs** (specifically reversible, centrally acting ones) inhibit the enzyme acetylcholinesterase, thereby increasing the concentration and duration of action of acetylcholine in the synaptic cleft. This helps improve cognitive function and delay symptomatic progression. * **Key Drugs:** Donepezil, Rivastigmine, and Galantamine. **2. Why the Other Options are Incorrect:** * **Multiple Sclerosis (MS):** This is an autoimmune demyelinating disorder of the CNS. Treatment involves disease-modifying therapies (e.g., Interferon-beta, Ocrelizumab) and steroids for acute relapses, not cholinergic enhancement. * **Guillain-Barré Syndrome (GBS):** This is an acute inflammatory demyelinating polyneuropathy (AIDP). Management focuses on supportive care, IVIG, or plasmapheresis. Anticholinesterases have no role here. * **To produce Mydriasis:** Mydriasis (dilation of the pupil) is produced by **Anticholinergics** (e.g., Atropine, Tropicamide) or Sympathomimetics (e.g., Phenylephrine). Anticholinesterases increase acetylcholine, which causes **Miosis** (constriction) by stimulating the sphincter pupillae. **3. High-Yield Clinical Pearls for NEET-PG:** * **Myasthenia Gravis:** The most common clinical use of peripheral anticholinesterases (Pyridostigmine is the drug of choice). * **Edrophonium:** Used in the **Tensilon Test** to differentiate between Myasthenic crisis (improvement) and Cholinergic crisis (worsening). * **Rivastigmine:** Unique among Alzheimer’s drugs as it is available as a **transdermal patch**, reducing GI side effects. * **Glaucoma:** Physostigmine or Echothiophate can be used to reduce intraocular pressure (though rarely first-line today).

Question 1

An elderly male is diagnosed with benign prostatic hypertrophy. Which drug will provide the fastest and greatest symptomatic relief for this patient?

Accepted Answer

Terazosin

Answer

Desmopressin

Answer

Finasteride

Answer

Sildenafil

Question 2

What is the rate-limiting step in the synthesis of norepinephrine?

Accepted Answer

Conversion of tyrosine to DOPA

Answer

Conversion of phenylalanine to tyrosine

Answer

Conversion of DOPA to dopamine

Answer

Conversion of dopamine to norepinephrine

Question 3

A drug X reverses the actions produced by the parasympathetic nervous system in the body but is not able to reverse the actions of exogenously administered acetylcholine in in-vitro experiments. What is the mechanism of drug X?

Accepted Answer

Inhibitor of the release of acetylcholine from synaptic vesicles

Answer

Acetylcholinesterase inhibitor

Answer

Muscarinic receptor antagonist

Answer

Muscarinic receptor agonist

Question 4

Which among the following is NOT a neuromuscular blocking agent?

Accepted Answer

Neostigmine

Answer

Pipecuronium

Answer

Gantacurium

Answer

d-TC

Question 5

Increasing the concentration of norepinephrine in adrenergic synapses leads to which of the following effects?

Accepted Answer

Activation of presynaptic Gi (C) coupled receptors

Answer

Activation of tyrosine hydroxylase

Answer

Activation of dopa decarboxylase

Answer

Increased release of norepinephrine

Question 6

All of the following drugs cause mydriasis except?

Accepted Answer

Pilocarpine

Answer

Phenylephrine

Answer

Epinephrine

Answer

Atropine

Question 7

All of the following are selective beta-blockers, except?

Accepted Answer

Celiprolol

Answer

Atenolol

Answer

Esmolol

Answer

Bisoprolol

Question 8

Which of the following is an example of antisialogogues used to control moisture during orthodontic bonding?

Accepted Answer

Banthine

Answer

Epinephrine

Answer

Betamethasone dipropionate

Answer

Paracetamol

Question 9

Which drug inhibits the release of acetylcholine at the neuromuscular junction?

Accepted Answer

Botulinum toxin

Answer

Hemicholinum

Answer

Atropine

Answer

Vesamicol

Question 10

Which condition is treated with anticholinesterase drugs?

Accepted Answer

Alzheimer's disease

Answer

Multiple sclerosis

Answer

Guillain Barre syndrome

Answer

To produce mydriasis

Autonomic Nervous System Drugs — MCQs

Autonomic Nervous System Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?